“…As the consumption of lupin has increased, so has the number of clinical cases reported in the literature (Table 1). In this context, two possible lupin sensitization pathways exist: a primary pathway involving ingestion [14–19, 23–30] or the inhalation of lupin flour [31–34], which is more common among allergic patients living in Mediterranean countries, where the diet typically compromises a great variety of legumes, and among these, lupin [33, 35], and in Australia [33], and a secondary pathway resulting from cross‐reactivity with the rest of the leguminous species, and particularly peanut [11, 16, 20, 36–41], soya [16] and peas [42] – this presentation being more frequent in North America [20] and in northern Europe [16, 36–39, 41]. Based on this secondary pathway, the percentages of clinical reactivity to lupin in patients with peanut allergy have varied depending on the methodology used and the patients studied, with figures ranging from 4% [41, 43] to 17.1% [6] or 37% [7].…”